Traws Pharma, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
12 PENNS TRAIL, NEWTOWN, PA, 18940
Mailing Address
12 PENNS TRAIL, NEWTOWN, PA, 18940
Phone
267-759-3680
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2024
$-22.57
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | March 10, 2026 | View on SEC |
| 4 Insider stock transaction report | March 10, 2026 | View on SEC |
| 4 Insider stock transaction report | March 10, 2026 | View on SEC |
| 4 Insider stock transaction report | March 10, 2026 | View on SEC |
| 4 Insider stock transaction report | March 10, 2026 | View on SEC |
| 4 Insider stock transaction report | March 10, 2026 | View on SEC |
| 4 Insider stock transaction report | March 10, 2026 | View on SEC |
| 4 Insider stock transaction report | March 10, 2026 | View on SEC |
| 4 Insider stock transaction report | March 10, 2026 | View on SEC |
| 8-K Current report of material events | February 19, 2026 | View on SEC |
Material Events
8-K
Other
February 19, 2026
High Impact
- Ratutrelvir (COVID-19 drug) shows positive Phase 2 results with significantly fewer side effects and no viral rebound compared to PAXLOVID®.
- Ratutrelvir offers faster symptom resolution for PAXLOVID®-ineligible patients, positioning it as a safer, more accessible alternative with potential to reduce 'Long COVID'.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.